IASLC Lightning Member Portal - 1 week
Loading×Sorry to interruptCSS...
Join us in 2 weeks at #SCLC23! A meeting focused on preclinical/clinical advances in #SCLC research, including basic research on oncogenesis & biology of disease, preclinical therapeutic research & highlights of ongoing clinical translation. Register https://t.co/bn7tcPelLA #LCSM https://t.co/bn7tcPelLA - view on twitter
Texas Lung Cancer Conference | IASLC - 7 days
We are excited to invite you to join us at the 1st Annual Texas Lung Cancer Conference in Austin, TX at the historic Austin...
Next week join the 1st Annual #TexasLung23 in Austin, TX @ the historic Austin City Limits. This 2-day CME-event will review the latest advances in #lungcancer focused on what a medical oncologist needs to know to provide state–of–the art care today. https://t.co/9ggoUVnvnP #LCSM https://t.co/9ggoUVnvnP - view on twitter
Mashup Score:11LUNGSTRONG 2018
LUNGSTONG | 5k Run - 2 days
Each year hundreds of runners and walkers come out in support of lung cancer research at this family-friendly event. 100% of race proceeds benefit...
Let's do this ‼️💪 🏃🏃♂️🏃♀️ #lungcancer #CancerResearch #LCSM @LUNGSTRONGorg @MGHCancerCenter @MGHThoracicOnc @JustinGainor https://t.co/PyUIR3cGXx - view on twitter
Mashup Score:11ILCN.org (ILCN/WCLC)
New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind – ILCN.org (ILCN/WCLC) - 3 days
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day...
The upcoming @TLCconference is a new IASLC-endorsed CME meeting tailored to busy clinicians. Drs. @StephenVLiu and Tina Cascone preview the program in #ILCN: https://t.co/WL8ErivGwf #TexasLung23 #LCSM - view on twitter
Mashup Score:11JTO Clinical and Research Reports
Durvalumab maintenance therapy following definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III non-small cell lung cancer (NSCLC). Although severe treatment-related...
Recovery from treatment-related lymphopenia (TRL) after chemoRT/on durva affects stage III NSCLC outcomes @JTOonline: - 151pts, 27% TRL recovery, 73% not - mPFS 21.9m v NR (p=0.018) favoring TRL grp - ⬆️pre-CRT ALC & TRL assoc w ⬆️PFS @Oncoalert #LCSM https://t.co/QBIJXPRz1D - view on twitter
Targeted Therapies – Consolidated Radiation | IASLC - 1 week
In this episode of Lung Cancer Considered, recorded at the 2023 Targeted Therapies of Lung Cancer meeting, host Dr. Narjust Florez moderates a conversation...
In this episode, recorded at #TTLC23, @NarjustFlorezMD moderates a conversation about the use of consolidated radiation in early-stage #SCLC. Joining the debate are Dr. Lawrence Einhorn (@IUMedSchool) & Dr. Charles Simone (@MSKCancerCenter). Listen: https://t.co/ft0qWTCeuy #LCSM https://t.co/ft0qWTCeuy - view on twitter
ClinicalTrials.gov Identifiers: NCT02367781, NCT02657434, and...
Longer #survival in patients with non-small cell #lungcancer with vs without mild to moderate Immune-Related Adverse Events with atezolizumab #immunotherapy Would be good to know if regardless treatment discontinuation #LCSM @OncoAlert @OncoViews https://t.co/74xgByK02r https://t.co/74xgByK02r - view on twitter
Mashup Score:8JTO Clinical and Research Reports
Participation in lung cancer screening (LCS) is lower in populations with the highest burden of lung cancer risk (through the social patterning of smoking...
Interventions Designed to Increase the Uptake of Lung Cancer Screening: An Equity-Oriented Scoping Review @oncologynursing @ASCO #oncoalert #LCSM https://t.co/BaQyZT7Txz - view on twitter
IASLC – STARS Scholar - 4 days
ALL INTERESTED PATIENT ADVOCATES: Please join us March 28 @ 10 AM MDT for a Zoom session where Janet Freeman-Daily (IASLC STARS Staff Consultant),...
Deadline Approaching! Apply by 4/2 for the STARS Scholars Program! A new opportunity for PRAs who want to attend #WCLC23 in person & have demonstrated active participation in PR advocacy activities. Learn more about the STARS Scholar program & Apply: https://t.co/DCVYfRwPD4 #LCSM https://t.co/DCVYfRwPD4 - view on twitter
Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) alterations are found in approximately 2-5% of non-small cell lung cancers (NSCLCs); the majority are...
Poziotinib in Treatment-Naïve HER2 Ex 20 Mutations: ZENITH20-4- Ph2 @JTOonline - N=80 - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash 45% stomatitis, diarrhea 15% - ⬆️ORR 71% in G778_P780dupGS ➡️ FDA declined 2nd line approval in 2022 pending more data #lcsm https://t.co/6CuMFdBTPk - view on twitter